Receptor Interacting Protein 2 (rip2) in Development of Immune Response

Innovation

UCLA investigators have determined that Receptor Interacting Protein 2 (RIP2) has novel functions in regulating Th1 helper T cells and the IL-1/IL-18 Toll-like receptor responses of NK cells and presents a target for therapeutic approaches to the treatment of disorders mediated by these cells, including toxic shock and certain autoimmune diseases. Their results suggest that RIP2 plays a pivotal role in Th1 and NK cell-mediated immune responses and that its regulation should provide a therapeutic approach to the treatment of disorders mediated by these cells, such as toxic shock and of certain autoimmune diseases.

Patent Status

Patent Pending